MedTrace Logo

Safety and Efficacy of Positron Emission Tomography Imaging With MNI-513

NCT01000870 · Status: TERMINATED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2010-10-06

No results posted yet for this study

Summary

The purpose of the study is to evaluate the efficacy and safety of MNI-513 positron emission tomography (PET) for detection/exclusion of cerebral amyloid beta in patients with Alzheimer's disease compared to healthy volunteers.

Conditions

  • Alzheimer Disease

Interventions

DRUG

MNI-513-01

Subjects will be administered a single IV injection of IMP with a total activity amounting to 300MBq (8.1 mCi) +/- 20% of MNI-513 followed by PET imaging.

Sponsors & Collaborators

  • Institute for Neurodegenerative Disorders

    lead OTHER

Principal Investigators

  • Danna Jennings, MD · Institute for Neurodegenerative Disorders

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2010-09-30
Completion
2010-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01000870 on ClinicalTrials.gov